Pharmaceuticals

Drug developers and pharmaceutical companies with approved products and research pipelines.

13 reports

Compare

Eli LillyLLY

A global drugmaker led by diabetes and obesity medicines.

Market cap: $1.1T
Net profit CAGR proj.: 29%
Operating margin: 46%
FCF yield 26e: 2.1%

Nyse · United States

RocheRO

A Swiss healthcare company spanning pharmaceuticals and diagnostics.

Market cap: $337B
Net profit CAGR proj.: 11%
Operating margin: 33%
FCF yield 26e: 5.5%

Swiss Exchange · Switzerland

NovartisNOVN

A global pharmaceutical company focused on innovative medicines.

Market cap: $292B
Net profit CAGR proj.: 7.9%
Operating margin: 34%
FCF yield 26e: 4.2%

Swiss Exchange · Switzerland

PfizerPFE

A global pharmaceutical company with vaccines, oncology, and specialty medicines.

Market cap: $139B
Net profit CAGR proj.: 7.4%
Operating margin: 31%
FCF yield 26e: 10%

Nyse · United States

RegeneronREGN

A biotechnology company focused on antibody-based medicines.

Market cap: $67B
Net profit CAGR proj.: 8.8%
Operating margin: 26%
FCF yield 26e: 8.9%

Nasdaq · United States

Johnson & JohnsonJNJ

A healthcare company focused on pharmaceuticals and medical technology.

Market cap: $633B
Net profit CAGR proj.: -0.8%
Operating margin: 28%
FCF yield 26e: 4.1%

Nyse · United States

MerckMRK

A global drugmaker led by oncology and vaccines.

Market cap: $320B
Net profit CAGR proj.: 8.6%
Operating margin: 38%
FCF yield 26e: 3.3%

Nyse · United States

Novo NordiskNOVO B

A global drugmaker led by diabetes and obesity treatments.

Market cap: $221B
Net profit CAGR proj.: -0.1%
Operating margin: 46%
FCF yield 26e: 2.9%

Nasdaq Copenhagen · Denmark

VertexVRTX

A biotechnology company best known for cystic fibrosis medicines.

Market cap: $134B
Net profit CAGR proj.: 15%
Operating margin: 39%
FCF yield 26e: 4.0%

Nasdaq · United States

AbbVieABBV

A pharmaceutical company built around immunology, oncology, neuroscience, and aesthetics.

Market cap: $461B
Net profit CAGR proj.: 73%
Operating margin: 35%
FCF yield 26e: 5.7%

Nyse · United States

AstraZenecaAZN

A global drugmaker led by oncology medicines.

Market cap: $300B
Net profit CAGR proj.: 16%
Operating margin: 24%
FCF yield 26e: 3.1%

London Stock Exchange · United Kingdom

AmgenAMGN

A biotechnology company focused on specialty medicines and biologics.

Market cap: $202B
Net profit CAGR proj.: 7.4%
Operating margin: 31%
FCF yield 26e: 5.5%

Nasdaq · United States

SanofiSAN

A global pharmaceutical company with vaccines, immunology, and rare-disease medicines.

Market cap: $103B
Net profit CAGR proj.: 9.9%
Operating margin: 21%
FCF yield 26e: 8.6%

Euronext Paris · France